IN8bio announces gamma-delta T cell enager platform

IN8bio (INAB) unveiled INB-600, its next generation gammadelta T cell-based TCE platform. It is designed to address one of the biggest shortcomings of current existing gammadelta TCEs – insufficient numbers of gammadelta T cell effector cells to drive real clinical impact. This groundbreaking platform leverages gammadelta T cells’ unique properties targeting applications in both oncology and autoimmune indications with potentially greater safety and tolerability than current CAR-T and TCE approaches. The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 demonstrated: Rapid and sustained B-cell depletion – target cells were eradicated as gammadelta T cells continued expanding up to 450-fold with continued proliferation until the target cells were undetectable. Simultaneous expansion and activation of both major gammadelta T cell subsets leverages both the rapid antigen presenting properties of Vdelta2+ T cells and the longer-term resistance against exhaustion and tissue residence properties of Vdelta1+ T cells, potentially resulting in deeper B cell depletion. Lower cytokine secretion, potentially reducing the risk of dangerous side effects such as CRS and ICANs, two of the most severe side effects limiting CAR-T and traditional CD3-TCE adoption in autoimmune indications.